Open access publisher BioMed Central has launched a new open access journal, Journal of Molecular Psychiatry, with its first published articles.
The new journal aims to disseminate state-of-the-art research focussing on psychiatric conditions, their diagnosis, therapy and prevention, by providing a platform for the rapid communication of scientific work focussing on the elucidation of the molecular and cellular mechanisms underlying neuropsychiatric disorders. The first articles to be published showcase the extensive range of topics covered in the journal. This includes a review discussing the use of post-mortem analysis of brain tissue as a possible tool to gain a deeper insight into the neurobiology of different psychiatric disorders, as well as an article reporting an investigation into the effect of Methylphenidate, a drug commonly used to treat ADHD, on neuronal stem cell differentiation.
Journal of Molecular Psychiatry will join BioMed Central's growing portfolio of psychiatry journals. The journal is supported by an expert Editorial Board.
